Atrial Fibrillation Innovation Program: Transitioning Emergency Atrial Fibrillation Management (Team) - Lessons From A Feasibility Trial

Abstract

s S99 single-shot acquisition T1 mapping sequence. Subjects also performed peak aerobic capacity (VO2) testing, a vertical jump test, and a wall squat test. RESULTS: Compared to controls, cancer survivors had significantly lower LVEF (57.5 6.2% vs. 64.3 5.5%, P<0.001), LV indexed mass (48.9 13.7 g/m vs. 62.7 10.2 g/m, P<0.001), LV mass/volume ratio (0.67 0.17 vs. 0.89 0.17, P<0.001), and peak VO2 (28.1 4.9 mL/kg/ min vs. 33.8 4.9 mL/kg/min, P<0.01). Between survivors and controls, there was no difference in myocardial ECVF (19.8 1.9% vs. 19.8 2.3%, P1⁄40.95), thigh ECVF (5.6 0.9% vs. 5.9 1.1%, P1⁄40.25), vertical jump distance (35.2 10.1 cm vs. 40.4 11.6 cm, P1⁄40.10), or wall squat duration (91 53 s vs. 111 58 s, P1⁄40.24). Myocardial ECVF and thigh ECVF were unrelated to cumulative anthracycline dose (r1⁄4-0.10, P1⁄40.54, and r1⁄4-0.11, P1⁄40.52, respectively). CONCLUSION: Asymptomatic childhood cancer survivors have significantly lower LVEF, LV mass, and LV mass/volume ratio, compared to controls, suggesting that conventional MRI is sensitive to early changes associated with anthracycline cardiotoxicity. Myocardial and thigh ECVF were similar between survivors and controls, suggesting that fibrosis is not a major component of these gross structural and functional changes. Long-term serial follow-up of a larger group of cancer survivors could provide further insight into the role of MRI in assessment of anthracyline cardiotoxicity in individual subjects. ACHRI Canadian Cardiovascular Society (CCS) Poster ATRIAL FIBRILLATION CLINICAL Thursday, October 17, 2013 030 ATRIAL FIBRILLATION INNOVATION PROGRAM: TRANSITIONING EMERGENCY ATRIAL FIBRILLATION MANAGEMENT (TEAM) LESSONS FROM A FEASIBILITY TRIAL N Meshkat, K Leblanc, S Bhatia, P Dorian, N Ivers, A Valentinis, L Ashley, AC Ha, K Benson, D Morra